Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 5/4/2005 First Published: 6/23/2004


1.		Phase I/II Study of Gimatecan in Patients With Recurrent or Progressive Primary Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0403029-01 SIGMATAU-ST-01-402, NCT00087061


2.		A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				20 and over				Pharmaceutical / Industry				CLBQ707A1101 NCT00410358


3.		An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Closed				20 and over				Pharmaceutical / Industry				CLBQ707A1101E1 NCT00441610


4.		Extension to Dose-Escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				CLBQ707A2101E1 NCT00462163


5.		A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				20 and over				Pharmaceutical / Industry				CLBQ707A1103 NCT00487058

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute